journal article·2023-02

Facile synthesis of curcumin-containing poly(amidoamine) dendrimers as pH-responsive delivery system for osteoporosis treatment

Xiaowei Yang, Zhihui Kuang, Xinmin Yang, Xin Hu, Peng Luo, Qi Lai, Bin Zhang, Xiaoyong Zhang, Yen Wei

Publisher page

Abstract

Osteoporosis is an age-related metabolic disease of bone, resulting in bone pain and even bone fragility and brittle fracture. Inhibiting overactive osteoclasts while promoting osteoblast activity is an ideal way to treat osteoporosis. Previous studies have demonstrated that natural compounds, such as curcumin (Cur) have dual roles both in promoting bone formation and inhibiting bone resorption, making them promising candidates for osteoporosis treatment. However, their poor water solubility, high dosage of curative effect and significant toxicity to other organs have largely limited their clinical translations. In this study, a novel method was reported to conjugate Cur and poly(amidoamine) dendrimers (PAD) using hexachlorocyclotriphosphazene (HCCP) as the linkage through a one-pot reaction, forming stable and uniform Cur loaded nanospheres (HCCP-Cur-PAD, HCP NPs). Owing to the hydrophilicity of PAD and hydrophobicity of Cur, HCP NPs can self-assemble into nanoparticles with particle size of 138.8 ± 78.7 nm and display excellent water dispersity. The loading capacity of Cur can reach 27.2% and it can be released from HCP NPs with pH-responsiveness. In vitro experimental results demonstrated that the HCP NPs entered lysosomes by endocytosis and proved dual anti-osteoporosis effects of inhibiting osteoclasts and promoting osteoblasts.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Bone health and treatments · Bone and Joint Diseases · Bone Metabolism and Diseases

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (79)

Show source-provided references
1. Exploring the treatment gap among patients with osteoporosis-related fractures in France10.1007/s11657-021-01041-1 ↗
2. Gossypol promotes Wnt/-catenin signaling through WIF1 in ovariectomy-induced osteoporosis10.1155/2019/8745487 ↗
3. Human metabolomics alteration associated with osteopenic and osteoporotic patients10.3390/metabo11090628 ↗
4. Bone quality: the material and structural basis of bone strength10.1007/s00774-007-0793-5 ↗
5. Bisphosphonate-enoxacin inhibit osteoclast formation and function by abrogating RANKL-induced JNK signalling pathways during osteoporosis treatment10.1111/jcmm.16949 ↗
6. Use of bisphosphonates in the management of postmenopausal osteoporosis
7. Bazedoxifene: a new selective estrogen receptor modulator for the treatment of postmenopausal osteoporosis10.1517/14656560902980228 ↗
8. Combined effect of teriparatide and an anti-RANKL monoclonal antibody on bone defect regeneration in mice with glucocorticoid-induced osteoporosis10.1016/j.bone.2020.115525 ↗
9. Zoledronic acid promotes osteoclasts ferroptosis by inhibiting FBXO9-mediated p53 ubiquitination and degradation10.7717/peerj.12510 ↗
10. Biomechanical mechanisms of atypical femoral fracture10.1016/j.jmbbm.2021.104803 ↗
11. Hormone therapy in the postmenopausal years: considering benefits and risks in clinical practice10.1093/humupd/dmab026 ↗
12. Raloxifene prevents early periprosthetic bone loss for postmenopausal women after uncemented total hip arthroplasty: a randomized placebo-controlled clinical trial10.1111/os.12696 ↗
13. Sarcoma arising in a patient with recurrent benign giant cell tumor of the proximal tibia while receiving treatment with denosumab10.1007/s11999-015-4249-2 ↗
14. Electroactive composite scaffold with locally expressed osteoinductive factor for synergistic bone repair upon electrical stimulation10.1016/j.biomaterials.2019.119617 ↗
15. Gadolinium-doped BTO-functionalized nanocomposites with enhanced MRI and X-ray dual imaging to simulate the electrical properties of bone10.1021/acsami.0c15837 ↗
16. Strategy to inhibit effective differentiation of RANKL-induced osteoclasts using vitamin D-conjugated gold nanoparticles10.1016/j.apsusc.2020.146765 ↗
17. Osteoblast differentiation and gene expression analysis on anodized titanium samples coated with graphene oxide10.1016/j.apsusc.2020.146646 ↗
18. Metal-phenolic networks as a promising platform for pH-controlled release of bioactive divalent metal ions10.1016/j.apsusc.2020.145569 ↗
19. Counting on natural products for drug design10.1038/nchem.2479 ↗
20. Identification of polyphenols from Rosa roxburghii Tratt pomace and evaluation of in vitro and in vivo antioxidant activity10.1016/j.foodchem.2021.131922 ↗
21. Anti-inflammatory Activity of Curcumin in Gel Carriers on Mice with Atrial Edema10.5650/jos.ess19212 ↗
22. Production, solubility and antioxidant activity of curcumin nanosuspension10.1590/1678-457X.6515 ↗
23. Curcumin nanoparticles: preparation, characterization, and antimicrobial study10.1021/jf104402t ↗
24. Synthesis and cytotoxic evaluation of monocarbonyl analogs of curcumin as potential anti-tumor agents10.1002/ddr.21291 ↗
25. Curcumin has immunomodulatory effects on RANKL-stimulated osteoclastogenesis in vitro and titanium nanoparticle-induced bone loss in vivo10.1111/jcmm.14842 ↗
26. Curcumin inhibits polyethylene-induced osteolysis via repressing NF-kappa B signaling pathway activation10.1159/000494537 ↗
27. Local administration of curcumin-loaded nanoparticles effectively inhibits inflammation and bone resorption associated with experimental periodontal disease10.1038/s41598-018-24866-2 ↗
28. Attenuation of oxidative stress-induced osteoblast apoptosis by curcumin is associated with preservation of mitochondrial functions and increased Akt-GSK3 beta signaling10.1159/000457945 ↗
29. Curcumin alleviates glucocorticoid-induced osteoporosis by protecting osteoblasts from apoptosis invivo and invitro10.1111/1440-1681.12513 ↗
30. Curcumin reduces apoptosis and promotes osteogenesis of human periodontal ligament stem cells under oxidative stress in vitro and in vivo10.1016/j.lfs.2021.119125 ↗
31. Curcumin modulates the crosstalk between macrophages and bone mesenchymal stem cells to ameliorate osteogenesis
32. Application of different nanocarriers for encapsulation of curcumin10.1080/10408398.2018.1495174 ↗
33. K. Deepak, C. Ravindra, M. Saraswati, G. Gangadhar, M. Ravindra, C. Raju, R.A. Venkataramanaiah, R. Devi, H. Shanavaz, D. Soumya, Preparation, characterization and antimicrobial activity of betel-leaf-extract-doped polysaccharide blend films, 9 (2021) 49–68.10.1680/jgrma.20.00014 ↗
34. Tailor-made electrically-responsive poly(acrylamide)-graft-pullulan copolymer based transdermal drug delivery systems: synthesis, characterization, in-vitro and ex-vivo evaluation
35. G. Divyashri, R.V. Badhe, B. Sadanandan, V. Vijayalakshmi, M. Kumari, P. Ashrit, D. Bijukumar, M.T. Mathew, K. Shetty, A.V. Raghu, Applications of hydrogel-based delivery systems in wound care and treatment: An up-to-date review, 33 (2022) 2025–2043.10.1002/pat.5661 ↗
36. PAMAM-modified citric acid-coated magnetic nanoparticles as pH sensitive biocompatible carrier against human breast cancer cells10.1080/03639045.2018.1451881 ↗
37. Magnetically polymeric nanocarriers for targeting delivery of curcumin and hyperthermia treatments toward cancer cells10.1002/pola.28150 ↗
38. A comparative study of curcumin-loaded lipid-based nanocarriers in the treatment of inflammatory bowel disease10.1016/j.colsurfb.2016.03.038 ↗
39. Preparation and characterization of curcumin loaded gold/graphene oxide nanocomposite for potential breast cancer therapy10.1007/s11164-018-3593-8 ↗
40. Gold nanoparticles generated and stabilized by water soluble curcumin-polymer conjugate: Blood compatibility evaluation and targeted drug delivery onto cancer cells10.1016/j.jcis.2011.11.024 ↗
41. Self-fluorescent and stimuli-responsive mesoporous silica nanoparticles using a double-role curcumin gatekeeper for drug delivery10.1016/j.cej.2016.04.087 ↗
42. Preparation and evaluation of ph sensitive novel anticancer drug carrier based on magnetic chitosan quartets10.1055/a-0855-8464 ↗
43. Cytotoxic activity and kinetic release study of lovastatin-loaded Ph-sensitive polymersomes10.1007/s11094-018-1888-0 ↗
44. A novel one-pot strategy for fabrication of PEGylated MoS2 composites for pH responsive controlled drug delivery10.1016/j.molliq.2020.112962 ↗
45. Highly cross-linked fluorescent poly(cyclotriphosphazene-co-curcumin) microspheres for the selective detection of picric acid in solution phase10.1039/C4TA06828A ↗
46. Biomimetic structures: biological implications of dipeptide-substituted polyphosphazene-polyester blend nanofiber matrices for load-bearing bone regeneration10.1002/adfm.201100275 ↗
47. Dual cross-linking systems of functionally photo-cross-linkable and thermoresponsive polyphosphazene hydrogels for biomedical applications10.1021/bm100197y ↗
48. Crosslinked polyphosphazene nanospheres with anticancer quercetin: synthesis, spectroscopic, thermal properties, and controlled drug release10.1007/s13233-018-6092-2 ↗
49. One-pot synthesis of acid-degradable polyphosphazene prodrugs for efficient tumor chemotherapy10.1039/D0TB01992E ↗
50. Synthesis of fluorescent dendrimers with aggregation-induced emission features through a one-pot multi-component reaction and their utilization for biological imaging10.1016/j.jcis.2017.09.039 ↗
51. Biodegradable cyclomatrix polyphosphazene nanoparticles: a novel pH-responsive drug self-framed delivery system10.1021/acsami.8b06114 ↗
52. D. Gangaraju, A.V. Raghu, P. Siddalingaiya Gurudutt, Green synthesis of γ-aminobutyric acid using permeabilized probiotic Enterococcus faecium for biocatalytic application, 3 (2022) 1436–1447.10.1002/nano.202200059 ↗
53. P. Ashrit, B. Sadanandan, L. Kyathsandra Natraj, K. Shetty, V. Vaniyamparambath, A.V. Raghu, A microplate-based Response Surface Methodology model for growth optimization and biofilm formation on polystyrene polymeric material in a Candida albicans and Escherichia coli co-culture, 33 (2022) 2872–2885.10.1002/pat.5753 ↗
54. Single walled carbon nanotubes in high concentrations is cytotoxic to the human neuronal cell LN1810.1016/j.rechem.2022.100484 ↗
55. Study of real-coded hybrid genetic algorithm (RGA) to find least-cost ration for non-pregnant dairy buffaloes
56. In vivo evaluation of a self-nanoemulsifying drug delivery system for curcumin10.1016/j.biopha.2017.01.102 ↗
57. Curcumin loaded nanostructured lipid carriers for enhanced skin retained topical delivery: optimization, scale-up, in-vitro characterization and assessment of ex-vivo skin deposition10.1016/j.ejps.2020.105438 ↗
58. Polyphosphazenes with amino acid citronellol ester side groups for biomedical applications10.1016/j.eurpolymj.2014.11.011 ↗
59. Comparison of the synthesis and bioerodible properties of N-linked versus O-linked amino acid substituted polyphosphazenes10.1007/s10904-013-9989-4 ↗
60. Icariin inhibits RANKL-induced osteoclastogenesis via modulation of the NF-kappa B and MAPK signaling pathways10.1016/j.bbrc.2018.11.201 ↗
61. Advances in osteoclast biology reveal potential new drug targets and new roles for osteoclasts10.1002/jbmr.1885 ↗
62. Small molecule T63 suppresses osteoporosis by modulating osteoblast differentiation via BMP and WNT signaling pathways10.1038/s41598-017-10929-3 ↗
63. Osteoclasts: new insights
64. Characterization of the osteoclast ruffled border chloride channel and its role in bone resorption10.1074/jbc.272.30.18636 ↗
65. Osteoclast differentiation and activation10.1038/nature01658 ↗
66. Selective regulation of MAPK signaling mediates RANKL-dependent osteoclast differentiation10.7150/ijbs.13814 ↗
67. Carboxypeptidase E is a novel modulator of RANKL-induced osteoclast differentiation10.14348/molcells.2014.0179 ↗
68. Involvement of PU.1 in NFATc1 promoter function in osteoclast development10.1016/j.alit.2015.01.006 ↗
69. Colorimetric and fluorescent TRAP assays for visualising and quantifying fish osteoclast activity
70. Icariin attenuates thioacetamide-induced bone loss via the RANKL-p38/ERK-NFAT signaling pathway10.3892/mmr.2022.12642 ↗
71. Erucin inhibits osteoclast formation via suppressing cell-cell fusion molecule DC-STAMP without influencing mineralization by osteoblasts10.1186/s13104-022-05988-3 ↗
72. Puerarin specifically disrupts osteoclast activation via blocking integrin-beta3 Pyk2/Src/Cbl signaling pathway
73. mTORC1 impedes osteoclast differentiation via calcineurin and NFATc110.1038/s42003-018-0028-4 ↗
74. Well-designed bone-seeking radiolabeled compounds for diagnosis and therapy of bone metastases10.1155/2015/676053 ↗
75. The role of tocotrienol in preventing male osteoporosis-a review of current evidence10.3390/ijms20061355 ↗
76. Association of microRNAs genes polymorphisms with arthritis: a systematic review and meta-analysis10.1042/BSR20190298 ↗
77. Bmal1 promotes cementoblast differentiation and cementum mineralization via Wnt/beta-catenin signaling10.1016/j.acthis.2022.151868 ↗
78. FGFR2 accommodates osteogenic cell fate determination in human mesenchymal stem cells10.1016/j.gene.2022.146199 ↗
79. Withanolide B promotes osteogenic differentiation of human bone marrow mesenchymal stem cells via ERK1/2 and Wnt/beta-catenin signaling pathways10.1016/j.intimp.2020.106960 ↗